Axsome Therapeutics Inc Investor R&D Call with Migraine Key Opinion Leaders (KOLs) Focusing on AXS-07
שיחת ועידה Axsome Therapeutics Inc
Axsome Therapeutics Inc Conference call or earnings call will be held on 25/11/2019 via an 800 number (toll-free). During the earnings conference call's session Axsome Therapeutics Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Axsome Therapeutics Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We are a clinical stage biopharmaceutical company developing novel therapies for the management of central nervous system, or CNS, disorders for which there are limited treatment options. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our product candidate portfolio includes two latestage candidates, AXS05 and AXS02, which we are developing for multiple indications. We have initiated a Phase 3 trial with AXS-05 in treatment resistant depression, or TRD, which we refer to as the STRIDE-1 study, and plan to initiate a Phase 2/3 trial in agitation in patients with Alzheimer's disease, or AD.קרא עוד שיחת ועידה